Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.

Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM.

J Clin Oncol. 2019 Jun 17:JCO1900189. doi: 10.1200/JCO.19.00189. [Epub ahead of print]

PMID:
31206316
2.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
3.

Tranexamic acid influences the immune response, but not bacterial clearance in a model of post-traumatic brain injury pneumonia.

Draxler DF, Awad MM, Hanafi G, Daglas M, Ho H, Keragala CB, Galle A, Roquilly A, Lyras D, Sashindranath M, Medcalf RL.

J Neurotrauma. 2019 May 29. doi: 10.1089/neu.2018.6030. [Epub ahead of print]

PMID:
31140372
4.

BRAF Mutation Class and Clinical Outcomes-Response.

Dagogo-Jack I, Awad MM, Shaw AT.

Clin Cancer Res. 2019 May 15;25(10):3189. doi: 10.1158/1078-0432.CCR-19-0422. No abstract available.

PMID:
31092613
5.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

PMID:
31086949
6.

Poroid hidradenoma of the scalp in an immunosuppressed patient.

Grant MT, Awad MM.

J Surg Case Rep. 2019 May 9;2019(5):rjz146. doi: 10.1093/jscr/rjz146. eCollection 2019 May.

7.

Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.

Kassab SE, Mowafy S, Alserw AM, Seliem JA, El-Naggar SM, Omar NN, Awad MM.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1062-1077. doi: 10.1080/14756366.2019.1613987.

8.

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M.

J Thorac Imaging. 2019 Apr 12. doi: 10.1097/RTI.0000000000000413. [Epub ahead of print]

PMID:
30985604
9.

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD.

Front Oncol. 2019 Mar 29;9:199. doi: 10.3389/fonc.2019.00199. eCollection 2019.

10.

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM.

J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6.

11.

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D.

Cancer Immunol Immunother. 2019 Jun;68(6):917-926. doi: 10.1007/s00262-019-02321-z. Epub 2019 Mar 15.

PMID:
30877325
12.

pCP13, a representative of a new family of conjugative toxin plasmids in Clostridium perfringens.

Watts TD, Vidor CJ, Awad MM, Lyras D, Rood JI, Adams V.

Plasmid. 2019 Mar;102:37-45. doi: 10.1016/j.plasmid.2019.02.002. Epub 2019 Feb 18.

PMID:
30790588
13.

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.

Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM.

Abdom Radiol (NY). 2019 May;44(5):1917-1927. doi: 10.1007/s00261-019-01935-2.

PMID:
30790009
14.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
15.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. No abstract available.

PMID:
30753829
16.

Lectin Activity of the TcdA and TcdB Toxins of Clostridium difficile.

Hartley-Tassell LE, Awad MM, Seib KL, Scarselli M, Savino S, Tiralongo J, Lyras D, Day CJ, Jennings MP.

Infect Immun. 2019 Feb 21;87(3). pii: e00676-18. doi: 10.1128/IAI.00676-18. Print 2019 Mar.

17.

Authors' Response.

Cheng MP, Marty FM, Costa DB, Awad MM.

J Thorac Oncol. 2018 Nov;13(11):e237. doi: 10.1016/j.jtho.2018.09.015. No abstract available.

PMID:
30368420
18.

Ergonomic analysis of laparoscopic and robotic surgical task performance at various experience levels.

Zárate Rodriguez JG, Zihni AM, Ohu I, Cavallo JA, Ray S, Cho S, Awad MM.

Surg Endosc. 2019 Jun;33(6):1938-1943. doi: 10.1007/s00464-018-6478-4. Epub 2018 Oct 22.

PMID:
30350099
19.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17.

PMID:
30224342
20.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
21.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

22.

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L.

J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.

PMID:
30138764
23.

Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression.

Abbas NAT, El Salem A, Awad MM.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1347-1360. doi: 10.1007/s00210-018-1544-y. Epub 2018 Aug 8.

PMID:
30090949
24.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

PMID:
30072474
25.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

PMID:
30017832
26.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

27.

Opioid Medication Use in the Surgical Patient: An Assessment of Prescribing Patterns and Use.

Tan WH, Yu J, Feaman S, McAllister JM, Kahan LG, Quasebarth MA, Blatnik JA, Eagon JC, Awad MM, Brunt LM.

J Am Coll Surg. 2018 Aug;227(2):203-211. doi: 10.1016/j.jamcollsurg.2018.04.032. Epub 2018 May 7.

PMID:
29746919
28.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

29.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Erratum in: Cancer Cell. 2019 Feb 11;35(2):329.

30.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.

31.

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM.

J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6. No abstract available.

PMID:
29631033
32.

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS.

Cancer Immunol Res. 2018 Jun;6(6):630-635. doi: 10.1158/2326-6066.CIR-17-0715. Epub 2018 Apr 5.

33.

Histological and immunohistochemical investigations of ovarian interstitial glands during non-breeding season in camels (Camelus dromedarius).

Awad MM, Mohamed RH, Amin YA, Hussein HA.

Reprod Domest Anim. 2018 Aug;53(4):872-879. doi: 10.1111/rda.13178. Epub 2018 Mar 30.

PMID:
29602226
34.

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. doi: 10.1158/1078-0432.CCR-18-0143. Epub 2018 Mar 22.

PMID:
29567812
35.

Comparison of precision and speed in laparoscopic and robot-assisted surgical task performance.

Zihni A, Gerull WD, Cavallo JA, Ge T, Ray S, Chiu J, Brunt LM, Awad MM.

J Surg Res. 2018 Mar;223:29-33. doi: 10.1016/j.jss.2017.07.037. Epub 2017 Nov 9.

PMID:
29433882
36.

Interim Analysis of a Prospective Multi-Institutional Study of Surgery Resident Experience with Flexibility in Surgical Training.

Cullinan DR, Wise PE, Delman KA, Potts JR, Awad MM, Eberlein TJ, Klingensmith ME.

J Am Coll Surg. 2018 Apr;226(4):425-431. doi: 10.1016/j.jamcollsurg.2017.12.024. Epub 2018 Jan 5.

37.

Bond strength of universal adhesives to air-abraded zirconia ceramics.

Al Jeaidi ZA, Alqahtani MA, Awad MM, Rodrigues FP, Alrahlah AA.

J Oral Sci. 2017;59(4):565-570. doi: 10.2334/josnusd.16-0666.

38.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

39.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG.

Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.

40.

Fundamentals of Laparoscopic Surgery: Not Only for Senior Residents.

Cullinan DR, Schill MR, DeClue A, Salles A, Wise PE, Awad MM.

J Surg Educ. 2017 Nov - Dec;74(6):e51-e54. doi: 10.1016/j.jsurg.2017.07.017. Epub 2017 Jul 27.

41.
42.

Adhesive Bonding to Computer-aided Design/ Computer-aided Manufacturing Esthetic Dental Materials: An Overview.

Awad MM, Alqahtani H, Al-Mudahi A, Murayshed MS, Alrahlah A, Bhandi SH.

J Contemp Dent Pract. 2017 Jul 1;18(7):622-626.

PMID:
28713119
43.

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM.

Clin Cancer Res. 2017 Oct 1;23(19):5737-5744. doi: 10.1158/1078-0432.CCR-17-1434. Epub 2017 Jul 5.

44.

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.

J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173.

PMID:
28557813
45.

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, Kulkarni M, Carretero J, Wang X, Warner-Hatten T, Cavanaugh JD, Osa A, Kumanogoh A, Freeman GJ, Awad MM, Christiani DC, Bueno R, Hammerman PS, Dranoff G, Wong KK.

J Thorac Oncol. 2017 Aug;12(8):1268-1279. doi: 10.1016/j.jtho.2017.04.017. Epub 2017 May 6.

46.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

47.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner J, Quayle SN, Wong KK.

Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.

48.

Useful alternative technique for tying a knot with one hand.

Musharbash FN, Awad MM.

Ann R Coll Surg Engl. 2017 Apr;99(4):338. doi: 10.1308/rcsann.2016.0361. No abstract available.

49.

More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer.

Zou T, Awad MM.

Ann Oncol. 2017 Apr 1;28(4):685-687. doi: 10.1093/annonc/mdx083. No abstract available.

PMID:
28327984
50.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28. Erratum in: Cancer Immunol Res. 2018 Apr;6(4):498-499.

Supplemental Content

Support Center